MedTrace Logo

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

NCT07749716 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-08-06

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

Conditions

Interventions

DRUG

Drug: VC005 tablets

VC005 repeat administration for 24 weeks

DRUG

VC005 tablets

VC005 repeat administration for 24 weeks

DRUG

VC005 placebo tablets

VC005 placebo repeat administration for 24 weeks

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • jianzhong Zhang · The Peking University People's Hospital, Beijing, Beijng

  • cheng zhou · The Peking University People's Hospital, Beijing, Beijng

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-15
Primary Completion
2028-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07749716 on ClinicalTrials.gov